We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

IFN-γ Signature Distinguishes Pediatric Hemophagocytic Lymphohistiocytosis from Sepsis and SIRS

By LabMedica International staff writers
Posted on 04 Oct 2021
Print article
Image: Photomicrograph of a bone marrow smear from a patient with hemophagocytic lymphohistiocytosis, showing foamy macrophages engulfing mature and precursor erythrocytes (arrow) (Photo courtesy of Ismail Hader, MD, FACP)
Image: Photomicrograph of a bone marrow smear from a patient with hemophagocytic lymphohistiocytosis, showing foamy macrophages engulfing mature and precursor erythrocytes (arrow) (Photo courtesy of Ismail Hader, MD, FACP)
Hemophagocytic lymphohistiocytosis (HLH), severe sepsis, and persistent systemic inflammatory response syndrome are all conditions defined by excessive immune activation that may progress rapidly and are associated high risk of death without early introduction of appropriate therapy.

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by pathologic immune activation in which prompt recognition and initiation of immune suppression is essential for survival. Children with HLH have many overlapping clinical features with critically ill children with sepsis and systemic inflammatory response syndrome (SIRS) in whom alternative therapies are indicated.

A large team of Pediatric Hematologists at the Baylor College of Medicine (Houston, TX, USA) collected sand processed blood samples of 40 patients with HLH and 47 pediatric patients with severe sepsis or SIRS. Plasma protein levels of 135 analytes representing cytokines, chemokines, and growth factors were determined using Milliplex MAP antibody panels (Millipore, Burlington, MA, USA) for the MagPix instrument (Luminex Corporation, Austin, TX, USA). Ferritin and interleukin-18 (IL-18) were analyzed in independent MagPix assays.

Peripheral blood mononuclear cells were sorted for CD3, CD4, CD8), and CD68 using the BD Aria Fusion (BD Bioscience, Franklin Lakes, NJ, USA). cDNA was prepared from CD3+8+ and CD368+ populations with the Nugen Ovation Pico WTA System V2 (Nugen, Redwood City, CA, USA). Gene expression data were generated using Affymetrix GeneChip Human Transcriptome Array 2.0 (Affymetrix, Santa Clara, CA, USA).

The scientists reported that 15 of 135 analytes were significantly different in HLH plasma compared with SIRS/sepsis, including increased interferon-γ (IFN-γ)–regulated chemokines CXCL9, CXCL10, and CXCL11. Furthermore, a 2-analyte plasma protein classifier including CXCL9 and interleukin-6 was able to differentiate HLH from SIRS/sepsis. Gene expression in CD8+ T cells and activated monocytes from blood were also enriched for IFN-γ pathway signatures in peripheral blood cells from patients with HLH compared with SIRS/sepsis.

Of the 40 pediatric HLH subjects, nine had biallelic gene mutations known to cause HLH (or monoallelic X-linked SH2D1A), four had single allele variants associated with HLH, and 11 had variants of uncertain significance in genes associated with immune functions potentially associated with immune dysregulation and HLH susceptibility.

The authors concluded that in their study they had identified differential expression of inflammatory proteins as a diagnostic strategy to identify critically ill children with HLH. Comprehensive unbiased analysis of inflammatory plasma proteins and global gene expression demonstrated that IFN-γ signaling is uniquely elevated in HLH. The study was published on September 10, 2021 in the journal Blood Advances.

Related Links:
Baylor College of Medicine
Millipore
Luminex Corporation
BD Bioscience
Nugen
Affymetrix


New
Gold Supplier
All-in-One Solution for All Molecular Testing
STARlet-AIOS
New
Automated Immunoassay System
GSD Thunderbolt
New
Silver Supplier
Automated RPR Syphilis Test
Automated RPR Test Kit
New
Gold Supplier
Fully Automated Batch Immunoanalyzer
Evidence+

Print article

Channels

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.